Should We Rethink The FDA Commissionership?

Should We Rethink The FDA Commissionership?
The U. S. Food and Drug Administration prides itself on being, first and foremost, all about science. So, how did the agency that regulates upwards of 30 percent of the U.S. economy get so caught up in tacking against biting political crosswinds? As a veteran of the regulatory wars, I believe the rocky seas began to roil when the position of FDA Commissioner became Senate confirmable in 1988. Prior to 1988, FDA Commissioners were appointed by the Secretary of HHS and thus not subject to Senate confirmation.

To be sure, Senate confirmation has added importance to the position of FDA Commissioner, and it brings the nominee into intimate contact with many members of Congress. That’s a positive. But the system of “holds” whereby senators haggle and bargain with the Commissioner-Designate over various matters is unseemly, if not improper.

Since 1988, addressing tough scientific and public policy issues has become even more difficult as the Commissioner now must often deflect the often politically motivated slings and arrows of elected officials. Dr. David Kessler, the second Senate-confirmed FDA Commissioner, made national headlines with his controversial efforts to regulate tobacco. More recent politicized issues include the approvals of Mifepristone (“the abortion pill”), Plan B (“the morning after pill”), Exondys 51 (for Duchenne’s Muscular Dystrophy), Aduhelm (for Alzheimer’s Disease), and policy issues such as drug importation, expanded access to experimental medicines (and related state and federal “Right-to-Try” legislation), medical marijuana, cannabidiol (CBD), and the more aggressive use of expedited drug review pathways. The current debate over the FDA’s COVID-19 Emergency Use Authorizations and other related decisions have undermined public confidence in the agency at a time when faith in our public health institutions is crucial in advancing our battle against the pandemic.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Baby formula shortage: ‘There is light at the end of the tunnel,’ former FDA exec says

Baby formula shortage: ‘There is light at the end of the tunnel,’ former FDA exec says

Peter Pitts, president of the Center for Medicine in the Public Interest, joins Yahoo Finance Live to discuss the ongoing...  Read more

Former FDA official rips Biden over handling of baby formula shortage: 'Smoke and mirrors'

Former FDA official rips Biden over handling of baby formula shortage: 'Smoke and mirrors'

Peter Pitts, a former FDA associate commissioner, joined 'Fox & Friends First' to discuss the Biden administration's hand...  Read more

Peter Pitts speaks to CNN about baby formula shortage
  • CNN
  • 05/13/2022 12:00 AM

Peter Pitts speaks to CNN about baby formula shortage

Former FDA Associate Commissioner Peter Pitts speaks with CNN on the shortage of baby formula on May 13, 2022....  Read more

DRUGWONKS BLOG